Biotechs Sepracor and Neurocrine Biosciences have seen shares soar as investors have seen potential for their entrants.

FORBES: Magazine Article

Sleeping pills such as Ambien from Sanofi-Aventis and Lunesta from Sepracor have been some of most heavily advertised drugs.

FORBES

Wall Street expects that neither Sepracor's Estorra nor Neurocrine's indiplon will have any limits on how long they can be taken.

FORBES: Sleep On Demand